Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480709 | 1.00 | ERN1 (0.47) | ERN1TDP1KMT2AMAPTMEN1 | |
| SCHEMBL30304192 | 0.86 | TDP1 (0.50) | ERN1TDP1KMT2AMAPTMEN1 | |
| SCHEMBL16797802 | 0.86 | TDP1 (0.50) | ERN1TDP1KMT2AMAPTMEN1 | |
| SCHEMBL30933788 | 0.82 | ERN1 (0.47) | ERN1TDP1MAPTHPGDALDH1A1 | |
| SCHEMBL4209586 | 0.82 | ERN1 (0.47) | ERN1TDP1MAPTHPGDALDH1A1 | |
| SCHEMBL16954082 | 0.82 | TSHR (0.41) | ERN1KMT2AMAPTMEN1HPGD | |
| SCHEMBL16957482 | 0.82 | LMNA (0.38) | KMT2AMAPTMEN1HPGDALDH1A1 | |
| SCHEMBL31006009 | 0.80 | DRD1 (0.42) | ERN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL16793397 | 0.80 | DRD1 (0.42) | ERN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL14785211 | 0.79 | ERN1 (0.44) | ERN1TDP1HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-107973809-B | Macrocyclic compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013022814-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2534152-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-102834397-A | Macrocyclic compounds as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2012-12-19 | — | — | CN | disclosed |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| CN-102753555-A | Macrocycles as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-24 | — | — | CN | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100402-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ERN1 1605/4885TDP1 2393/4885KMT2A 1111/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | ERN1 1605/4885TDP1 2393/4885KMT2A 1111/4885 |
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | ERN1 2413/4885TDP1 4282/4885KMT2A 4016/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | ERN1 1605/4885TDP1 2393/4885KMT2A 1111/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ERN1 874/4885TDP1 1596/4885KMT2A 1479/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ERN1 1605/4885TDP1 2393/4885KMT2A 1111/4885 |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ERN1 1605/4885TDP1 2393/4885KMT2A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.